Zymeworks M&A Deal with Theravance Biopharma, Inc.
Zymeworks Inc. filed an amendment to its previous 8-K to provide historical and pro forma financial statements following its completed acquisition of Theravance Biopharma, Inc. The merger involved a cash payment of $17.00 per share plus a contingent value right (CVR) tied to the future monetization and commercial success of ampreloxetine. The cash portion of the deal was financed through $350 million in non-recourse notes from OMERS Life Sciences and existing cash reserves.
- Counterparty
- Theravance Biopharma, Inc.